Bio plasma deep tech company Plasmapp (Youbong Lim, CEO) announced on the 22nd that it had submitted a securities registration statement to the Financial Services Commission and officially began the process of listing on the KOSDAQ market.

The total number of shares offered by Plasmapp is 1,771,000 shares, with a public offering price band of KRW 9,000 to KRW 11,000 per share, and the total offering amount is approximately KRW 159 billion to KRW 195 billion. Demand forecasts for institutional investors will be conducted on September 20th and 21st, followed by general subscriptions on the 26th and 27th. Plasmapp plans to list on the KOSDAQ market in October under the technology special listing track, with Mirae Asset Securities as the lead manager.

Plasmapp is a deep tech venture company that originated from the plasma laboratory at KAIST's Department of Physics in 2015. The company develops medical device care solutions starting with plasma technology, focusing on biological inactivation and regenerative activation solutions for surgical device low-temperature sterilization.

Plasmapp developed the world's only non-permeable sterilization pouch (STERPACK), enabling the development of the world's fastest 7-minute sterilization solution in the global medical device market. Plasmapp's medical sterilization device (STERLINK) received FDA certification in the United States in 2021, leading to approximately KRW 150 billion in global medical device market contracts.

Its regenerative activation solution, ACTILINK, the world's first medical implant surface treatment device using atmospheric low-pressure plasma, was launched in 2020, leading to over 100% annual growth in company revenue as its application expands within the medical market. Plasmapp expects to achieve over three times its current revenue in the fourth quarter of this year, surpassing last year's record quarterly revenue.

Plasmapp's technology consists of medical device packaging and plasma device technology, securing global market competitiveness through differentiated SW technology to maximize performance and HW element technology for economic efficiency. Plasmapp's three-stage core technology of consumables, SW, and HW forms entry barriers with 174 patent applications and a total of 43 global medical device certifications, including FDA, and expects to achieve high profitability through the cumulative increase in sales and the lock-in and entry barrier effects in the consumable business model.

Plasmapp's plasma surface treatment technology is also applied to the secondary battery's core process solutions and is expected to expand into the digital healthcare and medical 3D printing industries through the convergence of core technology elements, creating exclusive market opportunities and increasing profitability.

With its differentiated technology and the commercialization of world-first and only solutions, Plasmapp has been recognized for its growth potential and market expansion as a recipient of the Ministry of Trade, Industry and Energy's technology award, NET, NEP certification, the Ministry of Health and Welfare's innovative medical device company and new technology certification, the Ministry of SMEs and Startups' prospective unicorn, BIG 3 startup, top 100 SMEs, and recently as a D-unicorn company in Daejeon City.

Youbong Lim, CEO of Plasmapp, stated, "Through differentiated plasma technology and medical device care solutions in the global medical device industry, Plasmapp will leap into a global unicorn company."

Source: Edaily ( www.edaily.co.kr )